Cargando…

TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA

BACKGROUND: DNA methylation is an essential component for integrative diagnosis of gliomas. Methylation subtype prediction of gliomas is currently done via sample extraction of high-quality DNA (~1ug), methylome profiling, followed by probe identification, curation and subsequent analysis via differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Lita, Adrian, Sjöberg, Joel, Filipescu, Stefan, Celiku, Orieta, Petre, Luigia, Gilbert, Mark, Noushmehr, Houtan, Petre, Ion, Larion, Mioara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992223/
http://dx.doi.org/10.1093/noajnl/vdab024.084
_version_ 1783669329044176896
author Lita, Adrian
Sjöberg, Joel
Filipescu, Stefan
Celiku, Orieta
Petre, Luigia
Gilbert, Mark
Noushmehr, Houtan
Petre, Ion
Larion, Mioara
author_facet Lita, Adrian
Sjöberg, Joel
Filipescu, Stefan
Celiku, Orieta
Petre, Luigia
Gilbert, Mark
Noushmehr, Houtan
Petre, Ion
Larion, Mioara
author_sort Lita, Adrian
collection PubMed
description BACKGROUND: DNA methylation is an essential component for integrative diagnosis of gliomas. Methylation subtype prediction of gliomas is currently done via sample extraction of high-quality DNA (~1ug), methylome profiling, followed by probe identification, curation and subsequent analysis via different random forest classifiers. However, the DNA methylation classification is not always available for all the samples. Examples include when the existing material is not suitable for methylation profiling or the sample is very limiting. Therefore, we hypothesized that Raman spectroscopy might be suitable to predict the glioma methylome, based upon its ability to create a molecular fingerprint of the tumor and would provide biological insights unknown before. METHODS: Coherent Raman Spectroscopy was used for molecular fingerprinting of the regions of interest using 1mm(2) FFPE tissue spots from 39 patient samples with LGm1 to LGm6 methylation subtypes. Spectral information was then used to train a convolutional neural network (CNN) and develop a prediction algorithm, capable of detecting the glioma methylation subtypes. 70 % of the dataset was used for model training while the remaining 30% for validation. Oversampling was used to obtain a subtype-balanced data distribution. In addition, supervised wrapper methods and random forests were used to identify the top 50 most discriminatory Raman frequencies out of 1738. RESULTS: We demonstrate that Raman spectroscopy can accurately and rapidly classify gliomas according to their methylation subtype from achieved FFPE samples, which are routinely present in pathological laboratories as a complementary mean to obtain this important classification when other analyses are not available. The most discriminatory frequencies show differential spectral intensities depending upon the glioma subtypes across the larger areas of the tissue. CONCLUSIONS: The non-destructive nature of this method and the ability to be applied on FFPE samples directly, allows the histopathologist to reuse of the same slide for subsequent staining and downstream analyses.
format Online
Article
Text
id pubmed-7992223
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-79922232021-03-31 TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA Lita, Adrian Sjöberg, Joel Filipescu, Stefan Celiku, Orieta Petre, Luigia Gilbert, Mark Noushmehr, Houtan Petre, Ion Larion, Mioara Neurooncol Adv Supplement Abstracts BACKGROUND: DNA methylation is an essential component for integrative diagnosis of gliomas. Methylation subtype prediction of gliomas is currently done via sample extraction of high-quality DNA (~1ug), methylome profiling, followed by probe identification, curation and subsequent analysis via different random forest classifiers. However, the DNA methylation classification is not always available for all the samples. Examples include when the existing material is not suitable for methylation profiling or the sample is very limiting. Therefore, we hypothesized that Raman spectroscopy might be suitable to predict the glioma methylome, based upon its ability to create a molecular fingerprint of the tumor and would provide biological insights unknown before. METHODS: Coherent Raman Spectroscopy was used for molecular fingerprinting of the regions of interest using 1mm(2) FFPE tissue spots from 39 patient samples with LGm1 to LGm6 methylation subtypes. Spectral information was then used to train a convolutional neural network (CNN) and develop a prediction algorithm, capable of detecting the glioma methylation subtypes. 70 % of the dataset was used for model training while the remaining 30% for validation. Oversampling was used to obtain a subtype-balanced data distribution. In addition, supervised wrapper methods and random forests were used to identify the top 50 most discriminatory Raman frequencies out of 1738. RESULTS: We demonstrate that Raman spectroscopy can accurately and rapidly classify gliomas according to their methylation subtype from achieved FFPE samples, which are routinely present in pathological laboratories as a complementary mean to obtain this important classification when other analyses are not available. The most discriminatory frequencies show differential spectral intensities depending upon the glioma subtypes across the larger areas of the tissue. CONCLUSIONS: The non-destructive nature of this method and the ability to be applied on FFPE samples directly, allows the histopathologist to reuse of the same slide for subsequent staining and downstream analyses. Oxford University Press 2021-03-25 /pmc/articles/PMC7992223/ http://dx.doi.org/10.1093/noajnl/vdab024.084 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Supplement Abstracts
Lita, Adrian
Sjöberg, Joel
Filipescu, Stefan
Celiku, Orieta
Petre, Luigia
Gilbert, Mark
Noushmehr, Houtan
Petre, Ion
Larion, Mioara
TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA
title TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA
title_full TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA
title_fullStr TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA
title_full_unstemmed TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA
title_short TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA
title_sort tbmt-02. apollo: raman-based pathology of malignant glioma
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992223/
http://dx.doi.org/10.1093/noajnl/vdab024.084
work_keys_str_mv AT litaadrian tbmt02apolloramanbasedpathologyofmalignantglioma
AT sjobergjoel tbmt02apolloramanbasedpathologyofmalignantglioma
AT filipescustefan tbmt02apolloramanbasedpathologyofmalignantglioma
AT celikuorieta tbmt02apolloramanbasedpathologyofmalignantglioma
AT petreluigia tbmt02apolloramanbasedpathologyofmalignantglioma
AT gilbertmark tbmt02apolloramanbasedpathologyofmalignantglioma
AT noushmehrhoutan tbmt02apolloramanbasedpathologyofmalignantglioma
AT petreion tbmt02apolloramanbasedpathologyofmalignantglioma
AT larionmioara tbmt02apolloramanbasedpathologyofmalignantglioma